A pragmatic approach to the analysis of a combination formulation

The aim of the paper was to formulate a combined oral dosage form of rosuvastatin calcium and amlodipine besylate and to develop and validate an analytical method to be adopted for both routine quality control assay and in vitro dissolution studies of the formulation. The proposed combination formul...

Full description

Saved in:
Bibliographic Details
Main Authors: Noshin Mubtasim (Author), Eva Rahman Kabir (Author), Ashis Kumar Podder (Author), Subrata Bhadra (Author)
Format: Book
Published: Elsevier, 2016-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d6ed67ae67e14aebaea72d25d1fc8d3f
042 |a dc 
100 1 0 |a Noshin Mubtasim  |e author 
700 1 0 |a Eva Rahman Kabir  |e author 
700 1 0 |a Ashis Kumar Podder  |e author 
700 1 0 |a Subrata Bhadra  |e author 
245 0 0 |a A pragmatic approach to the analysis of a combination formulation 
260 |b Elsevier,   |c 2016-11-01T00:00:00Z. 
500 |a 1319-0164 
500 |a 10.1016/j.jsps.2015.06.004 
520 |a The aim of the paper was to formulate a combined oral dosage form of rosuvastatin calcium and amlodipine besylate and to develop and validate an analytical method to be adopted for both routine quality control assay and in vitro dissolution studies of the formulation. The proposed combination formulation has shown compatibility with the chosen excipients, verified through FT-IR study. A novel gradient RP-HPLC method was developed and validated according to the ICH guideline which was found to be suitable for the simultaneous estimation of rosuvastatin calcium and amlodipine besylate from the formulation. The retention time of 2.7 and 6.08 min allows the analysis of large amount of samples with less mobile phase which makes the method economic. The dissolution profiles of both the drugs in different dissolution medium were encouraging which makes the combination formulation of rosuvastatin calcium and amlodipine besylate superior and effective in achieving patient compliance. 
546 |a EN 
690 |a Rosuvastatin calcium 
690 |a Amlodipine besylate 
690 |a Compatible 
690 |a Combination formulation 
690 |a Method validation 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Saudi Pharmaceutical Journal, Vol 24, Iss 6, Pp 689-697 (2016) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1319016415001152 
787 0 |n https://doaj.org/toc/1319-0164 
856 4 1 |u https://doaj.org/article/d6ed67ae67e14aebaea72d25d1fc8d3f  |z Connect to this object online.